Forsante automatically reminds patients about their laboratory visits and sends them their laboratory results along with instructions via text message. The treating unit can monitor their patients through the service and will receive an alert if a patient has not attended their laboratory tests despite the reminder or if their laboratory results are abnormal.
The service utilizes logic-based artificial intelligence. The algorithms used can be customized to align with the practices of each healthcare organization.
Forsante implements approved clinical treatment guidelines.
Forsante’s core components are CE-marked medical devices. Forsante’s quality management system is ISO 13485 certified for the design, development, production, and sales of medical software.
Forsante Diabetes actively involves patients in their diabetes care. The service reminds patients of follow-up appointments and alerts healthcare professionals if a patient drops out of monitoring.
Forsante Diabetes provides an overview of all diabetic patients under care, as well as a dashboard that allows for a clear view of an individual patient’s condition. This makes the professional’s work easier, as all necessary diabetes treatment information is available in a single interface.
Forsante’s IRMA module generates reasoning based on symbolic artificial intelligence, along with explanations for its conclusions. The reasoning rules are customizable and can be modified as needed without requiring system training or validation with large datasets. The IRMA module is CE-marked as a Class IIb medical device.
Forsante PSA is a service that automates the monitoring of prostate cancer. It automatically reminds patients of laboratory visits and sends their PSA value along with instructions via text message. The treating unit monitors patients through the service and receives an alert if the patient does not attend laboratory tests despite reminders or if the specified PSA threshold or its rate of change is exceeded.
Forsante PSA follows monitoring protocols in accordance with the recommendations of the European Association of Urology, the Finnish Medical Society Duodecim, and the Finnish Urological Association.
The control module of the Forsante PSA service is CE-marked as a medical device. The service utilizes intelligent automation. The algorithms used can be customized to align with the practices of each healthcare organization.
Forsante CEA automates the monitoring of colorectal cancer. It automatically reminds patients of laboratory visits and sends their CEA value along with instructions via text message. The treating unit monitors patients through the service and receives an alert if the patient does not attend laboratory tests despite reminders or if the CEA threshold is exceeded.
Forsante Clozapine is a comprehensive solution for managing and monitoring patients undergoing clozapine treatment.
Forsante Clozapine ensures the safe progression of the treatment process by reminding patients of laboratory controls, interpreting laboratory results, and alerting healthcare professionals when necessary. The service follows EU Medicines Agency guidelines, providing recommended actions and dosage suggestions.
Forsante Clozapine reduces human errors associated with clozapine treatment. It minimizes treatment interruptions by reminding patients to take their medication and helps lower costs by reducing the need for complex and expensive treatment restarts.
Forsante Clozapine enables a seamless treatment process between primary and specialized healthcare.
Forsante’s AI-driven automation helps save critical healthcare resources and professionals’ time. It also provides justifications for the proposed treatment decisions. To ensure patient safety, the clozapine treatment management module will be CE-marked as a Class IIb medical device.
Forsante Anticoagulation is a comprehensive service for monitoring warfarin and direct oral anticoagulants (DOACs). The service automates anticoagulation treatment monitoring and patient documentation. Additionally, its warfarin module automates warfarin dosing, speeding up workflows and reducing human errors.
Forsante Anticoagulation saves up to 80% of the time doctors and nurses spend on anticoagulation treatment thanks to automation. It significantly improves treatment quality by standardizing care models, enhancing patient safetythrough automated dosing, and improving treatment balance. Treatment quality is tracked using the TTR value(Time in Therapeutic Range) and complication monitoring.
Monitoring DOAC therapy is crucial for minimizing the risk of complications. The European Society of Cardiology (ESC) recommends laboratory monitoring every four months for patients over 75 years old, especially those taking dabigatran. For other DOAC users, an annual check-up is recommended.
Forsante Anticoagulation enhances treatment quality and safety for DOAC patients. It ensures that patients attend check-ups regularly and receive automated notifications of their results. The service also provides healthcare organizations with a clear overview of DOAC patients and their treatment status.
The service adheres to both national and international treatment guidelines. To ensure patient safety, the warfarin treatment management module is CE-marked as a Class IIb medical device under the medical device directive.
